Trial reportJournal of child and adolescent psychopharmacology2013
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Trial report in Journal of child and adolescent psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00018902 (Treatment of SSRI-Resistant Depression in Adolescents), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Pooled it
- A systematic review of interventions for treatment resistant major depressive disorder in adolescents.European child & adolescent psychiatry · 2020Pooled it
- Emerging cardiovascular risk factors in childhood and adolescence: a narrative review.European journal of pediatrics · 2025Review
- Dosing of antidepressants in relation to body weight in children and adolescents with overweight.International journal of obesity (2005) · 2025Article
- Treatment-Resistant Mood Disorders.Pakistan journal of medical sciences · 2024Review
- Mechanisms Involved in the Link between Depression, Antidepressant Treatment, and Associated Weight Change.International journal of molecular sciences · 2024Review
- The association between a body shape index and depressive symptoms: a cross-sectional study using NHANES data (2011-2018).Frontiers in nutrition · 2024Article
- Predictors, Moderators, and Mediators Associated With Treatment Outcome in Randomized Clinical Trials Among Adolescents With Depression: A Scoping Review.JAMA network open · 2022Article
- Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.Journal of personalized medicine · 2021Article
- Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing.The mental health clinician · 2021Article
- Effectiveness of common antidepressants: a post market release study.EClinicalMedicine · 2021Article
- What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.Depression and anxiety · 2020Article
- High Prevalence of Metabolic Syndrome Among Adolescents and Young Adults With Bipolar Disorder.The Journal of clinical psychiatry · 2019Article
- Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys.The Journal of pediatrics · 2018Observational
- Association of mood disorders with cardiovascular disease risk factors in overweight and obese youth with elevated blood pressure.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Body Composition in Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors.Pediatrics · 2017Article
- Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review.International journal of molecular sciences · 2016Review
- Neural Plasticity in Obesity and Psychiatric Disorders.Neural plasticity · 2016Article
- Comanagement of Pediatric Depression and Obesity: A Clear Need for Evidence.Clinical therapeutics · 2015Review
- Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 4 countries.
Funding
Abstract
objectiveDepression and obesity are associated, but the impact of obesity on depression treatment outcome, or, conversely, the impact of treatment on body mass index (BMI) in depressed adolescents has not been reported. In this article, we examine the bidirectional relationships between BMI and treatment response in adolescents with treatment-resistant depression.
methodParticipants in the Treatment of Selective Serotonin Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) study had height and weight assessed at baseline, weekly for the first 6 weeks, biweekly for the next 6 weeks, and monthly from weeks 12 through 24. The impact of baseline BMI as a predictor and moderator of treatment response was assessed. In addition, participants' changes in BMI were assessed as a function of specific treatment assignment and treatment response.
resultsParticipants assigned to SSRIs had a greater increase in BMI-for-age-sex z-score and weight than did those assigned to venlafaxine. Post-hoc, those treated with paroxetine or citalopram had the biggest increases in BMI, relative to fluoxetine or venlafaxine. Overweight or obesity was neither a predictor nor a moderator of treatment outcome, nor of subsequent BMI change.
conclusionsOverweight status does not appear to affect treatment response in adolescents with resistant depression. The successful treatment of depression does not appear to favorably affect weight or BMI. Fluoxetine and venlafaxine are less likely to cause an increase in BMI than paroxetine or citalopram.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.